ClinicalTrials.Veeva

Menu
Medical Concierge Centrum Medyczne | Warsaw, Poland logo

Medical Concierge Centrum Medyczne | Warsaw, Poland

Research site

Site insights

Top conditions

Top treatments

Nadofaragene
Sasanlimab
LY3866288
Orforglipron
Semaglutide
Vepugratinib
Erdafitinib
allo-APZ2-OTS
Duocarmazine
Guselkumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Artur Radziszewski

Verified by this site

Active trials

9 of 13 total trials
Locations recently updated

A Study of Brenipatide in Adult Participants With Major Depressive Disorder (RENEW-MDD-1)

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying th...

Enrolling
Depressive Disorder, Major
Drug: Placebo
Drug: Brenipatide

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 3
Drug: Placebo

The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron work...

Enrolling
Urinary Incontinence,Stress
Drug: Placebo
Drug: Orforglipron

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder canc...

Active, not recruiting
Non-muscle Invasive Bladder Cancer
Drug: Bacillus Calmette-Guerin
Drug: PF-06801591

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladde...

Enrolling
Urinary Bladder Neoplasms
Neoplasm Metastasis
Drug: Vepugratinib
Drug: EV

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high...

Enrolling
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Drug: Pembrolizumab
Drug: Docetaxel

The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystr...

Active, not recruiting
Epidermolysis Bullosa
Drug: allo-APZ2-OTS
Drug: Placebo

Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the i...

Active, not recruiting
High-risk Non-muscle Invasive Bladder Cancer
Biological: Pembrolizumab
Biological: BCG

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladd...

Enrolling
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Drug: Nadofaragene Firadenovec

Trial sponsors

Lilly logo
Ferring logo
Janssen (J&J Innovative Medicine) logo
Novo Nordisk logo
MacroGenics logo
Merck Sharp & Dohme (MSD) logo
Pfizer logo
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems